KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 126 filers reported holding KALA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $72,000 | -81.6% | 59,719 | -60.1% | 0.00% | – |
| Q3 2021 | $392,000 | -81.5% | 149,513 | -62.6% | 0.00% | -100.0% |
| Q2 2021 | $2,117,000 | -32.7% | 399,464 | -14.4% | 0.00% | 0.0% |
| Q1 2021 | $3,145,000 | -2.6% | 466,712 | -2.0% | 0.00% | 0.0% |
| Q4 2020 | $3,228,000 | -9.8% | 476,019 | -0.2% | 0.00% | -50.0% |
| Q3 2020 | $3,579,000 | -28.6% | 477,085 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $5,014,000 | +19.2% | 477,085 | -0.4% | 0.00% | 0.0% |
| Q1 2020 | $4,207,000 | +138.1% | 478,891 | 0.0% | 0.00% | +100.0% |
| Q4 2019 | $1,767,000 | -4.0% | 478,891 | -0.9% | 0.00% | 0.0% |
| Q3 2019 | $1,840,000 | -35.3% | 483,374 | +8.4% | 0.00% | 0.0% |
| Q2 2019 | $2,844,000 | +20.2% | 446,003 | +55.8% | 0.00% | 0.0% |
| Q1 2019 | $2,367,000 | +89.2% | 286,184 | +11.9% | 0.00% | 0.0% |
| Q4 2018 | $1,251,000 | -19.3% | 255,760 | +62.7% | 0.00% | 0.0% |
| Q3 2018 | $1,551,000 | – | 157,169 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,430,021 | $9,638,000 | 6.26% |
| RA Capital Management | 10,874,613 | $73,295,000 | 1.10% |
| Mesirow Financial Investment Management, Inc. | 41,961 | $283,000 | 0.77% |
| Samsara BioCapital, LLC | 601,162 | $4,052,000 | 0.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $689,000 | 0.38% |
| Eventide Asset Management | 3,450,000 | $23,253,000 | 0.34% |
| Orbimed Advisors | 5,465,030 | $36,834,000 | 0.34% |
| Parkman Healthcare Partners LLC | 148,433 | $1,000,000 | 0.23% |
| Vivo Capital, LLC | 786,883 | $5,304,000 | 0.19% |
| Knights of Columbus Asset Advisors LLC | 199,954 | $1,348,000 | 0.13% |